Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 18/20 | 0.46 |
| ▸ | CAPNS1 | P04632 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623099 | 0.99 | CAPN1 (0.45) | CAPN1CAPNS1SMN1; SMN2 | |
| SCHEMBL3635784 | 0.90 | CAPN1 (0.39) | CAPN1CAPNS1 | |
| SCHEMBL4622798 | 0.89 | CAPN1 (0.42) | CAPN1CAPNS1SMN1; SMN2 | |
| SCHEMBL4806210 | 0.87 | CAPN1 (0.46) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4689653 | 0.79 | CPB2 (0.39) | — | |
| SCHEMBL5705285 | 0.78 | CAPN1 (0.33) | CAPN1CAPNS1 | |
| SCHEMBL3588879 | 0.78 | CAPN1 (0.47) | CAPN1CAPNS1 | |
| SCHEMBL4621195 | 0.77 | CTSK (0.62) | CAPN1 | |
| SCHEMBL4622199 | 0.77 | CTSK (0.62) | CAPN1 | |
| SCHEMBL27428208 | 0.77 | CAPN1 (0.57) | CAPN1CAPNS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465721-B2 | 2-hydroxytetrahydrofuran derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7384933-B2 | Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-06-10 | — | — | US | disclosed |
| EP-1701974-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-09-20 | — | — | EP | disclosed |
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-07-27 | — | — | US | disclosed |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-06 | — | — | US | disclosed |
| WO-2005056551-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | CAPN2, CAPN1, CAPNS1 | CAPN1 2/4885CAPNS1 3/4885SMN1; SMN2 793/4885 |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | CAPN1, MYH10, CAPN9 | CAPN1 1/4885CAPNS1 23/4885SMN1; SMN2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.